Sanara MedTech swings to Q3 2026 net loss from continuing operations of $1.29 million year over year
PUBT · 1d ago
Share
Listen to the news
- Sanara MedTech swung to a third-quarter 2026 loss from continuing operations of $1.3 million, partly due to merger-related costs.
- Net revenue rose 8% year-over-year to $28.4 million, driven by higher soft tissue repair product sales.
- Shareholders cleared the pending acquisition by MIMEDX in September; regulatory review remains underway.
- Full-year 2026 net revenue guidance fell to $110 million-$115 million from $116 million-$121 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanara Medtech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051394), on November 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending